Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer
作者:Md Ashraf-Uz-Zaman、Sadisna Shahi、Racheal Akwii、Md Sanaullah Sajib、Mohammad Jodeiri Farshbaf、Raja Reddy Kallem、William Putnam、Wei Wang、Ruiwen Zhang、Karina Alvina、Paul C. Trippier、Constantinos M. Mikelis、Nadezhda A. German
DOI:10.1016/j.ejmech.2020.112866
日期:2021.1
Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel
三阴性乳腺癌 (TNBC) 是一种侵袭性癌症,其特点是转移率和复发率较高,其中大约三分之一的 TNBC 患者患有脑转移。与此同时,TNBC 对化疗表现出良好的反应,这一特征推动了在该领域寻找具有治疗潜力的新型化合物。最近,我们已经鉴定出对选定细胞系具有细胞毒性并能够在体内穿过血脑屏障的新型尿素基化合物. 我们合成并分析了一个包含 40 多种化合物的库,以阐明导致所观察到的活性的关键特征。我们还将 FGFR1 确定为受这些化合物存在影响的分子靶标,使用计算机模型证实了我们的数据。总的来说,我们设想这些化合物可以进一步开发用于潜在的转移性乳腺癌治疗。